AMAG Pharmaceuticals and Allos Therapeutics Agree to Merge to Strengthen

AMAG Pharmaceuticals, Inc. AMAG and Allos Therapeutics, Inc. ALTH today announced that they have entered into a definitive merger agreement under which the companies will combine in an all-stock merger with a total equity value of approximately $686 million. The transaction is expected to result in annual cost savings synergies of between $55 million and $60 million, the majority of which are expected to be realized in the first fiscal year after closing.